Dr. Klein is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
750 Washington St
Boston, MA 02111Phone+1 617-636-5000Fax+1 617-636-6204
Education & Training
- Duke University HospitalFellowship, Hematology and Medical Oncology, 1998 - 2001
- Tufts Medical CenterResidency, Internal Medicine, 1995 - 1998
- Yale School of MedicineClass of 1995
Certifications & Licensure
- MA State Medical License 2001 - 2025
- NH State Medical License 2024 - 2024
- ME State Medical License 2020 - 2021
- NC State Medical License 1998 - 2001
- American Board of Internal Medicine Hematology
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014, 2016-2017, 2019-2022
- Super Doctor SuperDoctors.com
Clinical Trials
- Rituxan/BEAM vs Bexxar/BEAM in Autologous Hematopoietic Stem Cell Transplant for Non-Hodgkin's Lymphoma (BMTCTN0401) Start of enrollment: 2005 Dec 01
- Safety Study of High Dose Temozolomide to Treat Relapsed/Refractory Central Nervous System (CNS) Malignancy Start of enrollment: 2004 Apr 01
- A Phase II Study of Umbilical Cord Blood Transplantation Start of enrollment: 2005 Jul 01
- Join now to see all
Publications & Presentations
PubMed
- 20 citationsRapid and sustained decline in CXCL-10 (IP-10) annotates clinical outcomes following TNFα-antagonist therapy in hospitalized patients with severe and critical COVID-19...Hilal Hachem, Amandeep Godara, Courtney Schroeder, Daniel Fein, Hashim Mann
Journal of Clinical and Translational Science. 2021-01-01 - 8 citationsAssociation of Preexisting Heart Failure With Outcomes in Older Patients With Diffuse Large B-Cell Lymphoma.Jenica N Upshaw, Jason Nelson, Angie Mae Rodday, Anita J Kumar, Andreas K Klein
JAMA Cardiology. 2023-05-01 - 16 citationsPembrolizumab plus dinaciclib in patients with hematologic malignancies: the phase 1b KEYNOTE-155 study.Gareth P Gregory, Shaji Kumar, Ding Wang, Daruka Mahadevan, Patricia Walker
Blood Advances. 2022-02-22
Journal Articles
- Clinicopathologic Characteristics of Secondary Squamous Cell Carcinoma of Head and Neck in Survivors of Allogeneic Hematopoietic Stem Cell Transplantation for Hematolo...Kenneth B Miller, Kellie A Sprague, Chakra P Chaulagain, Esha Kaul, Andreas K Klein, Janet Cowan, Nature
Abstracts/Posters
- A Phase I/II Trial of Brentuximab Vedotin (BV) Plus Rituximab (R) As Frontline Therapy for Patients with Immunosuppression-Associated CD30+ and/or EBV+ LymphomasAndreas Klein, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- The Evaluation and Treatment (Tx) of Burkitt Lymphoma (BL) in the Modern Era: Real World (RW) Outcomes and Prognostication across 26 US Cancer Centers (CC)Andreas Klein, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Supervised Machine Learning Algorithms Using Patient Related Factors to Predict in-Hospital Mortality Following Acute Myeloid Leukemia TherapyAndreas Klein, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Press Mentions
- Center for Health Literacy Research + PracticeAugust 23rd, 2024
- Development and Clinical Application of CD19xCD3 and CD20xCD3 Bispecific AntibodiesJanuary 17th, 2022
- Old Idea, New Desperation: Can Plasma from Recovered Patients Help Those Now Battling COVID-19?May 22nd, 2020
- Join now to see all
Committees
- Chair, Tufts Health Sciences Institutional Review Board 2010 - Present
Professional Memberships
- Member
Other Languages
- Spanish, Chinese (Mandarin), Vietnamese, Portuguese, Thai, Chinese (Cantonese), Creole, Tamil, Croatian
External Links
- AndreasKleinMDhttp://www.linkedin.com/in/andreaskleinmd
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: